Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Add-On Cemiplimab Shows Promise as First-Line Treatment for Penile Cancer - 2 months ago Palbociclib Regimen Yields 'Incredible' PFS Gain in Metastatic Breast Cancer - 4 months ago Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC - 9 months ago PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma - about 1 year ago New First-Line Option for Pancreatic Cancer Approved - about 1 year ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - about 1 year ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - over 1 year ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - over 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - over 1 year ago FDA OKs First Drug for Nasopharyngeal Carcinoma - over 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - over 1 year ago Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer - over 1 year ago Pembrolizumab Wins FDA Approval in Operable Lung Cancer - over 1 year ago
2	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Libtayo available in Scotland for cervical cancer patients - 2 months ago Lynparza approved in Scotland for BRCA-mutated breast cancer patients - 2 months ago
3	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Adding Palbociclib to Standard Care Improved PFS in Triple-Positive Breast Cancer - 3 months ago Testing Elacestrant With Other Targeted Drugs for Metastatic Breast Cancer - 4 months ago Sequencing in Advanced Urothelial Carcinoma - 6 months ago Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPC - about 1 year ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - over 1 year ago Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer - over 1 year ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - over 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - over 1 year ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - over 1 year ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Tislelizumab in Combination With Chemotherapy for Gastric, Gastrosophageal Junction Adenocarcinoma - 4 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 8 months ago Pembrolizumab, Chemoradiotherapy Meet Overall Survival Endpoint for Cervical Cancer - about 1 year ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - about 1 year ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - over 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - over 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - over 1 year ago
5	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	SABCS 2024: Combination of Elacestrant and Abemaciclib Shows Promising Progression-Free Survival in ER+/HER2- Advanced Breast Cancer - 4 months ago Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - 5 months ago FDA Grants Breakthrough Therapy Designation to DS-8201a and T-DXd to Treat Metastatic Breast Cancer - 8 months ago FDA Approves Durvalumab Plus Chemotherapy to Treat Endometrial Cancer - 10 months ago Novel Chemotherapy Method Could Decrease Lung Cancer Tumor Size - about 1 year ago FDA Approves Irinotecan Liposome for Metastatic Pancreatic Adenocarcinoma - about 1 year ago FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma - over 1 year ago FDA Grants Priority Review for Pembrolizumab in Progressive Cervical Cancer - over 1 year ago
6	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Is New Standard of Care for High-Risk Early-Stage TNBC - 7 months ago
7	Elie Dolgin Nature Science journalist. Writes for eliedolgin.com. Somerville, Massachusetts science journalism	A Trojan horse for thirsty tumours - 9 months ago
8	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 10 months ago FDA Approves New Frontline Regimen for Aggressive ALL - about 1 year ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - over 1 year ago Non-Covalent BTK Inhibitor Approved for CLL - over 1 year ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Grants Fast Track Designation to PT886 for the Treatment of Pancreatic Cancer - about 1 year ago FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - about 1 year ago
10	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest - about 1 year ago

Journalists covering paclitaxel